Back to results
US 10,766,867 B2Granted
Hydantoins that modulate BACE-mediated APP processing
AssigneeBuck Institute for Research on Aging
InventorsVarghese John, Dale E. Bredesen
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBuck Institute for Research on Aging
InventorsVarghese John, Dale E. Bredesen
Estimating the term…
In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
A method of ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, said method comprising:
A method of ameliorating one or more symptoms of Alzheimer's disease, and/or reversing Alzheimer's disease, and/or reducing the rate of progression of Alzheimer's disease, said method comprising:
A method of slowing the progression, stopping, or reversing age-related macular degeneration (AMD) in a mammal, said method comprising administering to said mammal a hydantoin in an amount sufficient to slow the progression, stop, or reverse age-related macular degeneration in said mammal, wherein said hydantoin is a compound having a formula selected from the group consisting of:
A method for delaying the onset of a disease or a disorder, or reversing or retarding the progress of the disease or the disorder, or reducing the severity of the disease or the disorder, or alleviating one or more symptoms of the disease or the disorder, wherein the disease or the disorder is associated with BACE activity and characterized by the production of amyloid deposits and/or neurofibrillary tangles in a subject, wherein said method comprises providing to said subject a therapeutically effective amount of a hydantoin, wherein said hydantoin is a compound having a formula selected from the group consisting of:
Dependencies are inferred from the claim text.